The U.S. Food and Drug Administration today granted accelerated approval to Vyondys 53 (golodirsen) injection to treat Duchenne muscular dystrophy (DMD) patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. It is estimated that about 8 percent of patients with DMD have this mutation. DMD is a rare genetic disorder characterized by progressive muscle deterioration and weakness. It is the most common type of muscular dystrophy. DMD is caused by an absence of dystrophin, a protein that helps keep muscle cells intact.\u00a0Golodirsen is indicated for the treatment of Duchenne muscular dystrophy (DMD) in people who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping.<\/p>\n
If VYONDYS 53 (golodirsen) injection\u00a0<\/strong>are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj).<\/p>\n Note:<\/strong><\/em> VYONDYS 53 is given in a once-weekly infusion. VYONDYS 53 is used\u00a0to treat patients with Duchenne muscular dystrophy (DMD) who have a confirmed mutation in the\u00a0dystrophin<\/span><\/span><\/span>\u00a0gene that can be treated by skipping exon 53<\/b>.<\/p>\n
\nWe are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"VYONDYS 53 (golodirsen) injection, for intravenous use
\nInitial U.S. Approval: 2019<\/h2>\n